Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nuvectis Pharma, Inc. Director's Dealing 2023

Jul 10, 2023

33912_dirs_2023-07-10_8adfeaa1-a0a1-4a15-9c98-e0239c1150f8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2023-07-07

Reporting Person: Mosseri Marlio Charles (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-07-07 Common Stock P 8948 $15.19 Acquired 2541328 Direct

Footnotes

F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.07 to $15.19. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.